PHARMACOTHERAPY OF HEART FAILURE

Amberkar Mohanbabu Vittalrao; Harish Thanusubramanian; Meena Kumari K; Arshad Basha Shaik

doi:10.22159/ajpcr.2018.v11i6.23712

Authors

Amberkar Mohanbabu Vittalrao Department of Pharmacology, Kasturba Medical College, Manipal Academy of Higher Education, Manipal - 576 104, Karnataka, India
Harish Thanusubramanian Area Medical Advisor, Pfizer Ltd., Bandra - Kurla Complex, Bandra (East), Mumbai - 400 051, Maharashtra, India
Meena Kumari K Department of Pharmacology, Kasturba Medical College, Manipal Academy of Higher Education, Manipal - 576 104, Karnataka, India
Arshad Basha Shaik Department of Pharmacology, Kasturba Medical College, Manipal Academy of Higher Education, Manipal - 576 104, Karnataka, India

DOI:

https://doi.org/10.22159/ajpcr.2018.v11i6.23712

Keywords:

Digoxin diuretics Angiotensin converting enzyme inhibitors

Abstract

Abstract

Heart failure is one of the major problems related to heart diseases in the modern era. Multiple comorbidities like coronary artery disease, hypertension, diabetes mellitus, anemia etc. have a great contribution in the development of heart failure.It is primarily two types systolic and diastolic heart failure. Insufficient or decreased pumping of the heart is Systolic heart failure whereas diastolic heart failure is because of lack of ability of the heart to relax or increased muscle inflexibility. The pathophysiology of heart failure is due to enhanced activity of sympathetic system, Renin Angiotensin system and structural changes in the wall of ventricle. The two definite targets of medical treatment in heart failure are: (1) Alleviation of obstructive (or) decreased output manifestations and replenishment of cardiac function. The drugs used are Frusemide, thiazides,ACE inhibitors/ARBs,Amrinone/Milrinone,Dopamine/ Dobutamine,Levosimendan,Digoxin, Hydralazine,Nitroprusside, Nitrate, Bisoprolol,Metoprolol, Nebivolol, Carvedilol (2) Prevention ofadvancementof heart failure and extension of patient survival - drugs used are Î² blockers,ACE inhibitors/ ARBs, Spironolactone andEplerenone

Downloads

Download data is not yet available.

Author Biography

Amberkar Mohanbabu Vittalrao, Department of Pharmacology, Kasturba Medical College, Manipal Academy of Higher Education, Manipal - 576 104, Karnataka, India

Dept of Pharmacology,Associate Professor

References

Mann LD, Chakinala M. Heart failure and Corpulmonale. In: Longo DL, Kasper DL, Jameson JL, Fauci AS, Hauser SL, Loscalzo J, editors. Harrisonâ€™s Principles of Internal Medicine. 18th ed. New York: McGraw-Hill Medical Publishing Division; 2011. p. 1901-10.

Steinberg BA, Zhao X, Heidenreich PA, Peterson ED, Bhatt DL, Cannon CP, et al. Trends in patients hospitalized with heart failure and preserved left ventricular ejection fraction: Prevalence, therapies, and outcomes. Circulation 2012;126:65-75.

Sharma HL, Sharma KL. Drug Therapy of Heart Failure. 2nd ed. Ch. 22. New Delhi: Paras Medical Publisher;2002. p. 312-13.

Massie M. Heart failure: Pathophysiology. In: Goldman L, Scafer I editors. Goldmanâ€™s Cecil Medicine. 24th ed. Philadelphia: Elsevier publishers; 2012. p. 295-303.

Thomas P, Bradley A. Pharmacotherapy of congestive cardiac failure. In: Brunton L, Chabner A, Knollmann C, editors. Goodman & Gillmans The Pharmacological Basis of Therapeutics. 12th ed. San Diego: McGraw Hill Medical Publishing Division; 2011. p. 789-814.

Tripathi KD. Cardiac Glycosides and Drugs for Heart failure. 7th ed. Ch. 37. New Delhi: Jaypee Medical Publishers; 2013. p. 512-25.

Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997;336:525- 33.

Lewis GD, Lachmann J, Camuso J, Lepore JJ, Shin J, Martinovic ME, et al. Sildenafil improves exercise hemodynamics and oxygen uptake in patients with systolic heart failure. Circulation 2007;115:59-66.

Lehmann A, Boldt J, Kirchner J. The role of ca++-sensitizers for the treatment of heart failure. Curr Opin Crit Care 2003;9:337-44.

Toller WG, Stranz C. Levosimendan, a new inotropic and vasodilator agent. Anesthesiology 2006;104:556-69.

Husedzinovic I, Husedzinovic S, Milanovic R. Levosimendan in acute heart failure. Signa Vitae 2009;3 Suppl. 1:13-6.

Parker JO, Ibopamine Study Group. The effects of oral ibopamine in patients with mild heart failure: A double blind placebo controlled comparison to furosemide: The Ibopamine Study Group. Int J Cardiol 1993;40:221-7.

Dormans TP, van Meyel JJ, Gerlag PG, Tan Y, Russel FG, Smits P, et al. Diuretic efficacy of high dose furosemide in severe heart failure: Bolus injection versus continuous infusion. J Am Coll Cardiol 1996;28:376- 82.

Patterson JH, Adams KF Jr., Applefeld MM, Corder CN, Masse BR. Oral torsemide in patients with chronic congestive heart failure: Effects on body weight, edema, and electrolyte excretion. Torsemide investigators group. Pharmacotherapy 1994;14:514-21.

Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr. Drazner MH, et al 2013 ACCF/AHA guideline for the management of heart failure: A report of the American college of cardiology foundation/American heart association task force on practice guidelines. J Am Coll Cardiol 2013;62:e147-239.

Thanusubramanian H, Kishore MK, Shetty R, Amberkar MB. A Retrospective study of the treatment outcome of drug therapies used in heart failure patients with associated co-morbidities in a tertiary care hospital. J Clin Diagn Res 2016;10:FC06-9.

McMurray J, Pfeffer A. Heart failure: Management and prognosis. In: Goldman L, Scafer I, editors. Goldmanâ€™s Cecil Medicine. 24th ed. Philadelphia, PA: Elseviers Publishers; 2012. p. 304-17.

The Consensus Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). New Engl J Med 1987;316:1429.

Solvd Investigators, Yusuf S, Pitt B, Davis CE, Hood WB, Cohn JN,

et al. Effect of Enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.

Packer M, Poole-Wilson PA, Armstrong PW, Cleland JG, Horowitz JD, Massie BM, et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation 1999;100:2312-8.

Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative group on ACE inhibitor trials. JAMA 1995;273:1450-6.

Flather MD, Yusuf S, KÃ¸ber L, Pfeffer M, Hall A, Murray G, et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: A systematic overview of data from individual patients. ACE-inhibitor myocardial infarction collaborative group. Lancet 2000;355:1575-81.

McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, BÃ¶hm M, Dickstein K, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European society of cardiology. Developed in collaboration with the heart failure association (HFA) of the ESC. Eur J Heart Fail 2012;14:803-69.

Cohn JN, Tognoni G. Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345:1667-75.

McMurray JJ, Ã–stergren J, Swedberg K, Granger CB, Held P, Michelson EL, et al. CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: The CHARM-Added trial. Lancet 2003;362:767-71.

Granger CB, McMurray JJ, Yusuf S, Held P, Michelson EL, Olofsson B, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: The CHARM-alternative trial. Lancet 2003;362:772-6.

Maggioni AP, Anand I, Gottlieb SO, Latini R, Tognoni G, Cohn JN, et al. Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors. J Am Coll Cardiol 2002;40:1414-21.

Pitt B, Poole-Wilson PA, Segal R, Martinez FA, Dickstein K, Camm AJ, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: Randomised trial-the Losartan Heart Failure Survival Study ELITE II. Lancet 2000;355:1582-7.

Konstam MA, Neaton JD, Dickstein K, Drexler H, Komajda M, Martinez FA, et al. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): A randomised, double-blind trial. Lancet 2009;374:1840-8.

Torre-Amione G, Kapadia S, Benedict C, Oral H, Young JB, Mann DL, et al. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: A report from the studies of left ventricular dysfunction (SOLVD). J Am Coll Cardiol 1996;27:1201-6.

McMurray JJ, Pitt B, Latini R, Maggioni AP, Solomon SD, Keefe DL, et al. Effects of the oral direct renin inhibitor Aliskiren in patients with symptomatic heart failure. Circ Heart Fail 2008;1:17-24.

The cardiac insufficiency bisoprolol study II (CIBIS-II): A randomised trial. Lancet 1999;353:9-13.

Merit-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL randomised intervention trial in-congestive heart failure (MERIT-HF). Lancet 1999;353:2001-7.

Hjalmarson A, Goldstein S, Fagerberg B, Wedel H, Waagstein F, Kjekshus J, et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: The metoprolol CR/XL randomized intervention trial in congestive heart failure (MERIT-HF). MERIT-HF study group. JAMA 2000;283:1295- 302.

Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001;344:1651-8.

Packer M, Fowler MB, Roecker EB, Coats AJ, Katus HA, Krum H, et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure. Results of carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation 2002;106:2194-9.

Flather MD, Shibata MC, Coats AJ, Van Veldhuisen DJ, Parkhomenko A, Borbola J, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005;26:215-25.

Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol heart failure study group. N Engl J Med 1996;334:1349-55.

Beta-Blocker Evaluation of Survival Trial Investigators, Eichhorn EJ, Domanski MJ, Krause-Steinrauf H, Bristow MR, Lavori PW, et al. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med 2001;344:1659-67.

Poole-Wilson PA, Swedberg K, Cleland JG, Di Lenarda A, Hanrath P, Komajda M, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the carvedilol or metoprolol European trial (COMET): Randomised controlled trial. Lancet 2003;362:7-13.

MiraÃ§i M, Lezha M, Temali I, Matua L, Papajani V, Petrela E. Cost-effectiveness of beta blockers and the survival of the patients with heart failure in the cardiology center in Tirana. Int J Pharm Pharm Sci 2015;7:261-4.

Shailaja B, Swarna K, Afreen M, Kumar AA. A rapid assay method development and validation for the estimation of Eplerenone in tablets by UV spectrophotometry. Int J Pharm Pharm Sci 2015;7:327-30.

Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators. N Engl J Med 1999;341:709-17.

Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011;364:11-21.

Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309-21.

Cohn JN, Archibald DG, Ziesche S, Franciosa JA, Harston WE, Tristani FE, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a veterans administration cooperative study. N Engl J Med 1986;314:1547-52.

Taylor AL, Ziesche S, Yancy C, Carson P, Dâ€™Agostino Jr R, Ferdinand K, et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 2004;351:2049-57.

Cohn JN, Johnson G, Ziesche S, Cobb F, Francis G, Tristani F, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991;325:303-10.

Udelson JE, Smith WB, Hendrix GH, Painchaud CA, Ghazzi M, Thomas I, et al. Acute hemodynamic effects of conivaptan, a dual V1A and V2 vasopressin receptor antagonist, in patients with advanced heart failure. Circulation 2001;104:2417-23.

Gheorghiade M, Gattis WA, Oâ€™Connor CM, Adams KF Jr., Elkayam U, Barbagelata A, et al. Effects of Tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: A randomized controlled trial. JAMA 2004;291:1963-71.

Gheorghiade M, Niazi I, Ouyang J, Czerwiec F, Kambayashi JI, Zampino M, et al. Vasopressin V 2-receptor blockade with tolvaptan in patients with chronic heart failure: Results from a double-blind randomized trial. Circulation 2003;107:2690-6.

Konstam MA, Gheorghiade M, Burnett JC Jr., Grinfeld L, Maggioni AP, Swedberg K, et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: The EVEREST outcome trial. JAMA 2007;297:1319-31.

Gheorghiade M, Konstam MA, Burnett JC Jr., Grinfeld L, Maggioni AP, Swedberg K, et al. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: The EVEREST clinical status trials. JAMA 2007;297:1332-43.

Kothiya OM, Patel BA, Patel KN, Patel MM. Formulation and characterization of sustained release matrix tablets of ivabradine using 32 full factorial design. Int J Appl Pharm 2018;10:59-66.

Ramasubba K, Deswal A. Emerging strategies in treatment of heart failure. In: Acker M, Adams K, Anand I, Anker S, Avensea P, Baicu C, et al. editors. Heart Failure: A Companion to Braunwaldâ€™s Heart Disease. 2nd ed. Missouri: Elsevier Publishers; 2011. p. 728-39.

Swedberg K, Komajda M, Bohm M, Borer JS, Ford I, Dubost-Brama A, et al. SHIFT Investigators. Ivabradine and outcomes in chronic heart failure (SHIFT): A randomised placebo-controlled study. Lancet 2010;376:875-85.

Fox K, Ford I, Steg PG, Tendera M, Ferrari R, BEAUTIFUL Investigators. et al. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): A randomised, double-blind, placebo-controlled trial. Lancet2008;372:807-16.

Verma N. Introduction to hyperlipidemia and its treatment: A review. Int J Curr Pharm Res 2017;9:6-14.

Kjekshus J, Apetrei E, Barrios V, BÃ¶hm M, Cleland JG, Cornel JH, et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007;357:2248-61.

Tavazzi L, Maggioni AP, Marchioli R, Barlera S, Franzosi MG, Latini R, et al. Effect of rosuvastatin in patients with chronic heart failure (the GlSSI-HF trial): A randomised, double-blind, placebo-controlled trial. Lancet 2008;372:1231-9.

Tavazzi L, Maggioni AP, Marchioli R, Barlera S, Franzosi MG, Latini R, et al. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): A randomised, double-blind, placebo-controlled trial. Lancet 2008;372:1223-30.

Modlinger PS, Welch WJ. Adenosine A1 receptor antagonists and the kidney. Curr Opin Nephrol Hypertens 2003;12:497-502.

Gottlieb SS. Renal effects of adenosine A1-receptor antagonists in congestive heart failure. Drugs 2001;61:1387-93.

Gottlieb SS, Brater DC, Thomas I, Havranek E, Bourge R, Goldman S, et al. BG9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy. Circulation 2002;105:1348-53.

Greenberg B, Thomas I, Banish D, Goldman S, Havranek E, Massie BM, et al. Effects of multiple oral doses of an A1 adenosine antagonist, BG9928, in patients with heart failure: Results of a placebo-controlled, dose-escalation study. J Am Coll Cardiol 2007;50:600-6.

Cotter G, Dittrich HC, Weatherley BD, Bloomfield DM, Oâ€™connor CM, Metra M, et al. Protect Steering Committee. The PROTECT pilot study: A randomized, placebo-controlled, dose-finding study of the adenosine A1 receptor antagonist rolofylline in patients with acute heart failure and renal impairment. J Cardiac Fail 2008;14:631-40.

Forssmann W, Meyer M, Forssmann K. The renal urodilatin system: Clinical implications. Cardiovasc Res 2001;51:450-62.

Carstens JA, Jensen KT, Pedersen EB. Effect of urodilatin infusion on renal haemodynamics, tubular function and vasoactive hormones. Clin Sci 1997;92:397-407.

Bestle MH, Olsen NV, Christensen P, Jensen BV, Bie P. Cardiovascular, endocrine, and renal effects of urodilatin in normal humans. Am J Physiol 1999;276:R684-95.

Mitrovic V, Seferovic PM, Simeunovic D, Ristic AD, Miric M, Moiseyev VS, et al. Haemodynamic and clinical effects of ularitide in decompensated heart failure. Eur Heart J 2006;27:2823-32.

Gheorghiade M, Blair JE, Filippatos GS, Macarie C, Ruzyllo W, Korewicki J, et al. Hemodynamic, echocardiographic, and neurohormonal effects of istaroxime, a novel intravenous inotropic and lusitropic agent: A randomized controlled trial in patients hospitalized with heart failure. J Am Coll Cardiol 2008;51:2276-85.

Ashrafian H, Horowitz JD, Frenneaux MP. Perhexiline. Cardiovasc Drug Rev 2007;25:76-97.

Lee L, Campbell R, Scheuermann-Freestone M, Taylor R, Gunaruwan P, Williams L, et al. Metabolic modulation with perhexiline in chronic heart failure: A randomized, controlled trial of short-term use of a novel treatment. Circulation 2005;112:3280-8.

Aussedat J, Ray A, Kay L, Verdys M, Harpey C, Rossi A, et al. Improvement of long-term preservation of isolated arrested rat heart: Beneficial effect of the antiischemic agent trimetazidine. J Cardiovasc Pharmacol 1993;21:128-35.

Fragasso G, Palloshi A, Puccetti P, Silipigni C, Rossodivita A, Pala M, et al. A randomized clinical trial of trimetazidine, a partial free fatty acid oxidation inhibitor, in patients with heart failure. J Am Coll Cardiol 2006;48:992-8.

Fraser H, Belardinelli L, Wang L, Light PE, McVeigh JJ, Clanachan AS. Ranolazine decreases diastolic calcium accumulation caused by ATX-II or ischemia in rat hearts. J Mol Cell Cardiol 2006;41:1031-8.

McCormack JG, Barr RL, Wolff AA, Lopaschuk GD. Ranolazine stimulates glucose oxidation in normoxic, ischemic, and reperfused ischemic rat hearts. Circulation 1996;93:135-42.

Maier LS, Layug B, Karwatowska-Prokopczuk E, Belardinelli L, Lee S, Sander J, et al. RAnoLazIne for the treatment of diastolic heart failure in patients with preserved ejection fraction: The RALI-DHF proof-of-concept study. JACC Heart Fail 2013;1:115-22.

Siliprandi N, Sartorelli L, Ciman M, Di L. Carnitine-metabolism and functions. Physiol Rev 1989;631420-80.

Tripp ME, Katcher ML, Peters HA, Gilbert EF, Arya S, Hodach RJ, et al. Systemic carnitine deficiency presenting as familial endocardial fibroelastosis: A treatable cardiomyopathy. N Engl J Med 1981;305:385- 90.

Anand I, Chandrashekhan Y, De Giuli F, Pasini E, Mazzoletti A, Confortini R, et al. Acute and chronic effects of propionyl-L-carnitine on the hemodynamics, exercise capacity, and hormones in patients with congestive heart failure. Cardiovasc Drugs Ther 1998;12:291-9.

Gu J, Noe A, Chandra P, Al-Fayoumi S, Ligueros-Saylan M, Sarangapani R, et al. Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi). J Clin Pharmacol 2010;50:401-14.

Fala L. Entresto (Sacubitril/Valsartan): first-in-class angiotensin receptor neprilysin inhibitor FDA approved for patients with heart failure. American health and drug benefits. 2015;8(6):330.

McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014;371:993-1004.